Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA)

International Journal of Cancer

Volumn 81, Issue 2, 1999, Pages 285-291

  Robert, Bruno ^a   Dorvillius, Mylène ^a   Buchegger, Franz ^b   Garambois, Véronique ^a   Mani, Jean Claude ^c   Pugnières, Martine ^c   Mach, Jean Pierre ^d   Pèlegrin, André ^a,e  

^a CENTRE VAL D AURELLE   (France)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIV MONTPELLIER   (France)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e Faculty of Medicine   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ANTIGEN BINDING; ARTICLE; CANCER IMMUNOTHERAPY; COLON CARCINOMA; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN IMMOBILIZATION; RADIOIMMUNOASSAY; RADIOIMMUNOTHERAPY; SURFACE PLASMON RESONANCE; TUMOR LOCALIZATION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; CARCINOEMBRYONIC ANTIGEN; EPITOPES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; KINETICS; MICE; MICE, NUDE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032941030     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990412)81:2<285::AID-IJC19>3.0.CO;2-T     Document Type: Article

References (27)

1. AMOROSO, A.R., CLARK, J.I., LITWIN, S., HSIEH-MA, S., SHI, T., ALPAUGH, R.K., ADAMS, G.P., WOLF, E.J., RING, D.B. and WEINER, L.M., Binding characteristics and antitumor properties of 1A10 bispecific antibody recognizing gp40 and human transferrin receptor. Cancer Res., 56, 113-120 (1996).
2. BEGENT, R.H.J. and 12 OTHERS, Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat. Med., 2, 979-984 (1996).
3. BUCHEGGER, F., MACH, J.P., PÈLEGRIN, A., GILLET, M., VOGEL, C.A., BUCLIN, T., RYSER, J.E., DELALOYE, B. and BISCHOF-DELALOYE, A., Radiolabeled chimeric anti-CEA monoclonal antibody compared with the original mouse monoclonal antibody for surgically treated colorectal carcinoma. J. nucl. Med., 36, 420-429 (1995).
4. 2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J. Nucl. Med., 31, 1035-1044 (1990).
5. CASEY, J.L., KING, D.J., CHAPLIN, L.C., HAINES, A.M.R., PEDLEY, R.B., MOUNTAIN, A., YARRANTON, G.T. and BEGENT, R.H.J., Preparation, characterisation and tumor targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments. Brit. J. Cancer, 74, 1397-1405 (1996).
6. CHEONG, H.S., CHANG, J.S., PARK, J.M. and BYUN, S.M., Affinity enhancement of bispecific antibody against two different epitopes in the same antigen. Biochem. biophys. Res. Comm., 173, 795-800 (1990).
7. COOK, A.G. and WOOD, P.J., Chemical synthesis of bispecific monoclonal antibodies: potential advantages in immunoassay systems. J. Immunol. Methods, 171, 227-237 (1994).
8. 2 fragments from monoclonal anticarcinoembryonic antigen antibodies. J. clin. Invest., 77, 301-311 (1986).
9. FRANÇOIS, C., BOEFFARD, F., KALUZA, B., WEIDLE, U.H. and JACQUES, Y., Construction of a bispecific antibody reacting with the alpha-and beta-chains of the human IL-2 receptor. High affinity cross-linking and high anti-proliferative efficiency. J. Immunol., 150, 4610-4619 (1993).
10. HAMMARSTRÖM, S. and 30 OTHERS, Antigenic sites in carcinoembryonic antigen. Cancer Res., 49, 4852-4858 (1989).
11. HOLLIGER, P., PROSPERO, T. and WINTER, G., "Diabodies": small bivalent and bispecific antibody fragments. Proc. nat. Acad. Sci. (Wash.), 90, 6444-6448 (1993).
12. 2. J. nucl. Med., 37, 1504-1510 (1997).
13. KAMINSKI, M.S. and 12 OTHERS, Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med., 329, 459-465 (1993).
14. KING, D.J. and 19 OTHERS, Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. Brit. J. Cancer, 72, 1364-1372 (1995).
15. LE DOUSSAL, J.M., CHETANNEAU, A., GRUAZ-GUYON, A., MARTIN, M., GAUTHEROT, E., LEHUR, P.A., CHATAL, J.F., DELAAGE, M. and BARBET, J., Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. J. nucl Med., 34, 1662-1671 (1993).
16. MACH, J.-P., PÈLEGRIN, A. and BUCHEGGER, F., Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors. Curr. Opin. Immunol., 3, 685-693 (1991).
17. MOFFAT, F.L., JR., PINSKY, C.M., HAMMERSHAIMB, L., PETRELLI, N.J., PATT, Y.Z., WHALEY, F.S. and GOLDENBERG, D.M., Clinical utility of external immunoscintigraphy with the IMMU-44 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group. J. clin. Oncol., 14, 2295-2305 (1996).
18. NERI, D., MOMO, M., PROSPERO, T. and WINTER, G., High-affinity antigen binding by chelating recombinant antibodies (CRAbs). J. mol. Biol., 246, 367-373 (1995).
19. PLUCKTHUN, A. and PACK, P., New protein engineering approaches to multivalent and bispecilic antibody fragments. Immunotechnology, 3, 83-105 (1997).
20. PRESS, O.W., EARY, J.F., APPELBAUM, F.R., MARTIN, P.J., NELP, W.B., GLENN, S., FISHER, D.R., PORTER, B., MATTHEWS, D.C., GOOLEY, T. and BERNSTEIN, I.D., Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 346, 336-340 (1995).
21. ROBERT, B., MACH, J.P., MANI, J.C., YCHOU, M., FOLLI, S., ARTUS, J.C. and PÈLEGRIN, A., Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor α. Cancer Res., 56, 4758-4765 (1996).
22. TERSKIKH, A., COUTY, S., PÈLEGRIN, A., HARDMAN, N., HUNZIKER, W. and MACH, J.-P., Dimeric recombinant IgA directed against carcino-embryonic antigen, a novel tool for carcinoma localization. Moll. Immunol., 31, 1313-1319 (1994).
23. TERSKIKH, A., MACH, J.-P. and PÈLEGRIN, A., Marked increase in the secretion of a fully antigenic recombinant CEA obtained by deletion of its hydrophobic tail. Mol. Immunol., 30, 921-927 (1993).
24. TERSKIKH, A.V., LE DOUSSAL, J.M., CRAMERI, R., FISCH, I., MACH, J.P. and KAJAVA, A.V., "Peptabody": a new type of high avidity binding protein. Proc. nat. Acad. Sci. (Wash.), 94, 1663-1668 (1997).
25. WELT, S., DIVGI, C.R., KEMENY, N., FINN, R.D., SCOTT, A.M., GRAHAM, M., GERMAIS, J.S., RICHARDS, E.C., LARSON, S.M., OETTGEN, H.F. and OLD, L.J., Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J. clin. Oncol., 12, 1561-1571 (1994).
26. WERLEN, R.C., LANKINEN, M., OFFORD, R.E., SCHUBIGER, P.A., SMITH, A. and ROSE, K., Preparation of a trivalent antigen-binding construct using polyoxime chemistry: improved biodistribution and potential for therapeutic application. Cancer Res., 56, 809-815 (1996).
27. 2 in patients with non-reseclable liver metastases from colorectal cancer. Int. J. Cancer. 75, 615-619 (1998).